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Abstract: Photodynamic therapy (PDT) is an alternative cancer treatment to conventional surgery, radiotherapy 
and chemotherapy. It is based on activating a drug with light that triggers the generation of cytotoxic species that 
promote tumour cell killing. At present, PDT is mainly used in the treatment of wet age-related macular 
degeneration, for precancerous conditions of the skin (e.g. actinic keratosis) and in the palliative care of advanced 
cancers, for instance of the bladder or the oesophagus. Due to a lack of phase III clinical trials and limitations of 
light penetration to deeper lying tumours (in excess of 1 cm), PDT is still not used as a first line cancer treatment, 
which is surprising given the first clinical trials by Dougherty’s group dating back to the 1970’s. However research 
continues to demonstrate the potential benefits of PDT and the need to stimulate funding and uptake of clinical 
studies using next generation photosensitizers offering advanced targeted delivery, improved photodynamic dose 
combined with modern light delivery technologies. This review surveys the available PDT treatments and 
emerging novel developments in the field with a particular focus on two-photon techniques that are anticipated to 
improve the effectiveness of PDT in tissues at depth and on next generation drugs that work without the need of 
the presence of oxygen for photosensitization making them effective where hypoxia has taken hold. 
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1. INTRODUCTION TO PDT 
 More than 200 types of cancers are known to date with 
different levels of severity and a variety of characteristics [1, 
2]. This creates a need for novel and advanced treatment 
modalities beyond the classical approaches of surgery, 
chemotherapy and radiotherapy. PDT is such an alternative 
treatment modality, which on its own or in combination with 
the classical treatments aims to provide improved clinical 
outcomes and long term remission for cancer patients. The 
main advantages of clinically approved PDT include its 
minimal invasiveness (minimized scarring) compared with 
surgical tumour removal, reduced likelihood to develop 
multidrug resistance (MDR) and selectivity towards 
malignant cells restricting unwanted side-effects towards 
collateral healthy tissue compared with chemotherapy [3-6]. 
 Traditionally the term PDT means the use of light of a 
specific wavelength (commonly provided by a red lamp or a 
laser) and a photoactivatable drug (referred to as the 
photosensitizer (PS)) that upon absorption of light undergoes 
electronic excitation and generates either directly or 
indirectly cytotoxic agents (see Figure 1A) that include for 
example reactive oxygen species, sensitized usually via a 
triplet energy transfer (see section 4.1 Photochemistry of 
photosensitizers). The highly reactive oxygen species (ROS) 
have the ability to locally destroy cancerous tissue in a 
patient [4, 5, 7-12]. In the clinic PDT treatment commonly 
consists of two stages (Figure 1B). 
 Following PDT treatment photosensitivity of the skin can 
occur, lasting from a few days up to a few weeks because of 
slow excretion of PS molecules from the patient’s body. This 
prolonged sensitivity to light usually forces the patient to 
avoid direct exposure to sunlight until the drug is discharged. 
Accurately specifying the dosimetry of PS administered and 
light dose can help to reduce this unwanted side-effect [3, 
10, 13-15]. Another major limitation of PDT is the depth the 
activating light can penetrate into tissue at the excitation 
wavelength [4, 16], as well as the inactivity of many 
photosensitizers in hypoxic environments, which restricts 
formation of ROS, such as commonly found in tumour cores. 
The therapeutic outcome of PDT depends on a wide range of 
treatment parameters including the light source, light fluence 
(W/cm2), the method used to illuminate the tissue, tissue 
type, tissue oxygenation, specificity of the drug to a certain 
cancer type, and the PS [17]. 
Please provide 
corresponding author(s) 
photograph
2    AntiCancer Agents in Medicinal Chemistry, 2016, Vol. 0, No. 0 Scherer  et al. 
 PDT was originally developed for the localized treatment 
of solid tumours, but presently it is more commonly used in 
the clinical treatment of early cancers of the lung, 
oesophagus (Barrett’s oesophagus), skin (actinic keratosis, 
squamous and basal cell carcinoma, but not melanoma), 
bladder, breast, cervix, mouth, intestines and lungs. The 
effectiveness of PDT towards other cancers e.g. of the head 
and neck, bile duct, pancreas, prostate, and brain is being 
investigated in clinical studies. PDT is primarily applied to 
the targeted treatment of superficial cancers (e.g. of the skin) 
and cancers that are easy to reach by endoscopic fibres, as 
light penetration in tissue, particularly in the visible 
Figure 1 Different types of photodynamic therapy (PDT) based on the reaction mechanism of the photosensitizer (PS) used and key steps of PDT in 
the clinic. A There exist direct (oxygen-independent) and indirect (requiring oxygen) mechanisms of photosensitization in PDT depending on the PS 
being used. Most PSs used in the clinic demonstrate the Type II mechanism, but other PSs have been proposed that use the direct Type III and IV 
mechanism and are also effective in hypoxic tissues, where Type I and II photosensitization is limited. B In the clinic PDT treatment commonly 
consists of two stages. First the patient is administered a suitable dose of a light-activatable photosensitizer (PS) (usually by intravenous injection or 
topical as a cream), which is allowed to accumulate in the body with selectivity to the tumour site. The accumulation can take minutes to days 
depending on the PS used and location at the target site. Secondly, PS accumulation is followed by irradiation directly at the location of the diseased 
tissue site (e.g. tumour) with an intense light source (usually a laser) of a defined wavelength matching the PS absorption spectrum thus leading to the 
formation of an excited state. A dominant form of decay of the excited state PS is to transfer energy (sensitize) molecular oxygen so that it comes into 
contact with or reacts with cellular constituents generating reactive oxygen species (ROS) such as singlet oxygen and oxygen radicals (Type I & II). 
Singlet oxygen is highly reactive and cytotoxic, and hence causes damage to the irradiated cells eventually leading to selective apoptosis or necrosis in 
the treated tissue and tumour shrinkage [4, 5, 7, 15, 18-22]. 
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wavelength range is limited. Other conditions that have been 
successfully treated using PDT include macular 
degeneration, particularly using two-photon PS activation, 
and bacterial infections [3-5, 20, 23-28]. 
 Although PDT is successfully applied to treat a range of 
cancers it can also have significant drawbacks depending on 
the PS and light source used, location of the malignant lesion 
or tissue oxygenation level. PDT PSs often lack selectivity 
towards neoplastic tissues, which may lead to the generation 
of reactive oxygen species and cellular damage (burns, 
swelling, pain) in surrounding healthy tissues upon 
excitation [14, 17, 28, 29]. The highly localized nature of 
PDT makes it mostly unsuitable for the treatment of 
metastases [5].  
 In the UK the National Institute for Health and Clinical 
Excellence (NICE) has approved PDT for use in certain 
types of skin cancer and internal cancers that can be reached 
by laser light within a few millimetres of the tumour 
particularly when located near the lining of internal organs 
and for superficial lesions. In the clinic, PDT is mainly used 
in palliative care or to cure early cancers and some pre-
cancerous conditions. In the treatment of more advanced 
cancers PDT is often used in combination with other 
treatment modalities with the aim of tumour size reduction 
and symptom relief. It is still very much at a developmental 
stage for the treatment of many conditions and is hence often 
given to patients as part of a clinical trial. Unfortunately 
there is only a small number of advanced (phase III) trials 
because of funding cuts. PDT can be offered in an outpatient 
service, which is cost-effective and saves the patient a 
hospital stay [5, 20, 27]. A recent review focuses specifically 
on the use of PDT for the treatment of malignant brain 
tumours and provides a detailed and up-to-date summary of 
clinical investigations undertaken by numerous groups 
around the World [30]. It also highlights the difficulty in 
fully assessing the clinical impact of PDT because of the 
lack of control studies. Even though PDT is recognised by 
the NHS (National Health Service, UK) as an effective, 
licensed cancer treatment according to the information 
published on their official UK website  concern is expressed 
about unproven and unlicensed versions of PDT that are 
being marketed by some private clinics in the UK and 
overseas (Mexico and China). These include so called “next-
generation PDT (NGPDT)” and “sonodynamic therapy 
(SDT)”, applying ultrasound to activate a PS [27]. 
 Nevertheless there is still a significant amount of 
research ongoing in the development of novel PSs and their 
targeted delivery to tumours as can be seen by the number of 
publications in the field that have been continuously 
increasing since the 1960’s (Figure 2).  
 It is only through the continued and indeed sustained 
fundamental development of novel PSs and treatment 
protocols that PDT will become a viable technique to treat 
cancer. This review surveys the use of PDT in the clinic and 
covers the current developments in the field. We emphasize 
and put into context new approaches using two-photon, as 
opposed to single photon, methods and identify new 
potential sensitizers that introduce a novel Type IV PDT 
mechanism that have greater potential to target cancer in 
hypoxic environments. 
 
 
Figure 2 Development of publication numbers per year on photodynamic 
therapy since 1960 as found on Web of Science (WoS, filter to include: 
articles, reviews and patents) and NCBI PubMed (Search: photodynamic 
therapy). 
2. HISTORY OF PDT 
The use of sunlight (“heliotherapy”) to treat conditions such 
as vitiligo, rickets, psoriasis, psychosis, and even skin cancer 
was recognized by ancient civilisations including the 
Egyptians, Indians, Chinese and Greek [7, 31]. Nonetheless 
it took until the late 18th century before an early form of 
phototherapy for the treatment of smallpox and cutaneous 
tuberculosis using an artificial red light source was 
developed by Niels Finsen. For his work using a “Finsen” 
lamp the Danish scientist was awarded the Nobel Prize in 
1903 [31]. Around the same time in 1900 Oscar Raab, a 
student of Professor Herman von Tappeiner, observed cell 
death in paramecia cultures when treating them with a 
combination of acridine red and light irradiation. In the same 
laboratory the term “photodynamic action” was coined when 
it was recognized that oxygen was essential to induce the 
observed cell killing. This discovery triggered a substantial 
amount of research into various aspects of PDT including the 
mechanisms of photodynamic processes, new PSs and 
clinical studies. The first PDT clinical trials were reported in 
1905 using eosin and Magdala red as PSs. The PS 
hematoporphyrin, a precursor of porphyrin which is still 
commonly used in photodynamic treatments to date, was 
first used in preclinical experiments on mice by Hausmann 
in 1911. Two years later the German scientist, Friedrich 
Meyer-Betz administered himself with 200 mg of the PS 
intravenously to test its effectiveness in humans. He 
experienced swelling and soreness in body parts that were 
exposed to sunlight.  
 The first detailed studies of the effects of oxygen 
presence and the role of reactive singlet oxygen (1O2) in PDT 
of cancer cells using hematoporphyrin derivative (HpD) as 
PS were reported by Moan et al. in the late 1970’s. They 
reported that lower O2 concentrations resulted in a reduced 
PDT effect and that hypoxic tumour cells demonstrated 
resistance to the PDT. They hence suggested to enrich 
hypoxic tissues with oxygen during the treatment. Another 
group reported on patients with oesophageal cancer who 
showed improved outcomes when the treatment was carried 
out under increased pressure (2 absolute atmospheres) 
compared with conventional PDT under atmospheric 
pressure [32]. 
 The discovery that porphyrins preferentially localize and 
fluoresce in tumour tissue, the purification of HpD from 
crude hematoporphyrin [33-37] and the fact that it could be 
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activated by red light led to the first trials using HpD as a PS 
by Thomas Dougherty’s group in the 1970s. Exciting results 
were obtained in the treatment of cutaneous and 
subcutaneous malignant tumours with tumour regression 
being observed in 111 cases. However, photosensitization of 
the skin for up to 6 weeks following administration of the PS 
was found to be a major side-effect of this treatment [4, 7, 
31, 32, 38, 39]. Despite the promising results achieved by 
Dougherty and his co-workers, the first controlled clinical 
trials using HpD as PDT PS were only started in the mid-
1980’s – mid-1990’s by Quadra Logic Technologies (QLT) 
Photo Therapeutics (Canada) and American Cyanamid (NY). 
These clinical studies led to the approval of the PS 
Photofrin® (purified derivative of HpD) for the palliative 
treatment of bladder cancer in 1993 and later oesophageal, 
cervical and lung cancer in a few countries [7, 10]. Since 
then PDT has also been approved for the clinical treatment 
of conditions other than cancer such as wet age-related 
macular degeneration (AMD) using Visudyne® (2001). By 
2009 a range of other PSs had been approved by the FDA 
including Foscan®, Levulan®, Metvix® and Hexvix® [7]. 
3. MECHANISMS OF PDT 
3.1. Photochemistry of photosensitizers 
There exist two distinct approaches to PDT, direct and 
indirect, the terms defining the chemical involvement of the 
PS and cellular entity. The most established clinically are the 
indirect mechanisms, Type I and II. Many of these PSs show 
a combination of Types I and II oxygen-dependent reaction 
pathways. Types III and IV rely on the direct activation of 
the photosensitizer that once activated requires no secondary 
oxygen-dependent reactions to induce cell death (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Type I photodynamic processes radical species (OH˙, 
O2˙ˉ and others) are formed by electron transfer to oxygen 
from an excited PS (e.g. furocoumarins). The resulting 
reactive oxygen species (ROS) oxidize intracellular 
biomolecules such as nucleic acids, amino acids or 
unsaturated lipids eventually leading to cell death. In type II 
mechanisms, singlet oxygen is formed by energy transfer 
from the excited state PS (e.g. porphyrins) to molecular 
oxygen. On a photochemical basis Type II photosensitization 
is initiated by the absorption of a photon of light by the PS, 
thereby lifting it from its ground (S0, 2 paired electrons with 
opposite spin) to an excited electronic state (S1, one electron 
transferred to higher energy molecular orbital). Relaxation 
from the S1 state back to the ground state can progress via 
different pathways, such as the emission of a photon 
(fluorescence), heat (non-radiative decay) or alternatively 
intersystem crossing (ISC) to the more stable triplet state 
(inverted electron spin), which has a comparatively long 
lifetime (~ 100 nano- to several microseconds). If oxygen 
(O2) is present the triplet state PS may transfer the excess 
energy to the ground state molecular oxygen (triplet oxygen, 
3O2) leading to the formation of singlet oxygen (1O2). Singlet 
oxygen has a relatively short nanosecond (~ 10 – 320 ns) 
lifetime in biological systems and hence has a short radius of 
action (10 – 55 nm) through diffusion, thus the intracellular 
PS localization is important in achieving efficient PDT. Type 
II reactions are thought to be the most common pathway in 
photodynamic reactions. In Type III reactions a triplet-
doublet interaction between the PS and free radicals takes 
place exerting a cytotoxic effect towards intracellular 
structures without the need for oxygen. This mechanism is 
thought to compete with Type I and II photosensitization. 
Type III PSs are usually Antioxidant Carrier Sensitizers 
(ACS), also called Modified Type I (MTO) PSs, which 
combine properties leading to the efficient generation of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
singlet oxygen and decreasing the concentration of native 
free radicals in malignant cells. ACS are usually synthesized 
from the molecular backbone of originally active PSs used in 
clinical PDT, such as substituted porphyrin derivatives [5, 
10, 15, 17, 19, 24, 26, 28, 29, 40-44]. Currently novel types 
of pro-drugs such as combretastatins, discussed fully in 
section 4.4, are emerging which can be directly photo-
Figure 3 Simplified Jablonski diagram showing the electronic energy levels and  the underlying photochemical mechanisms of PDT indicating indirect 
processes that require the presence of tissue oxygen (Type I & II), as well as direct mechanisms in which no oxygen is required (Type II and IV) and the 
PS interacts directly with its subcellular target to induce cell killing. Type I and II mechanisms frequently occur at the same time with Type II usually being 
the dominating process (ISC = intersystem crossing). 
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activated by multiphoton excitation without the need for the 
presence of oxygen within the target tissue (see the section 
on Alternative Strategy for Two-photon Phototherapy (2P-
PDT) without ROS below). We suggest here a novel Type 
IV mechanism will be described in detail below (section 
5.4). In brief it involves a PS that cannot bind its molecular 
target and only upon excitation with light undergoes 
intramolecular remodelling (by photoisomerization) that than 
facilitates binding of the activated PS to its cellular target 
site. 
3.2. Action of PDT at the tissue and cellular level 
 Over the years there has been a wide range of studies 
investigating the interaction and distribution of light in 
tissues, this being fundamental to the successful activation of 
PSs in vivo. The Patterson group started studying the light 
propagation within tissues in the 1980’s when they realized 
that an understanding of light-tissue interactions is critical to 
ensure that sufficient light reaches the treatment site as well 
as to obtain precise dosimetry for PDT. Their early models 
(using Monte Carlo simulations) were based on the use of 
630 nm light on tissues in combination with the PS HpD. 
Absorption and scattering are considered the two main 
processes leading to light attenuation in tissues, which are 
highly heterogeneous turbid media. The fluence rate of light 
at a specific wavelength and its depth distribution are 
characteristic for each tissue type and depend on 
pigmentation levels [43, 45-49]. Wavelengths in the near-
infrared (NIR) region (typically 600 – 1100 nm) penetrate 
deepest into biological tissues. This wavelength range, where 
tissues are most transparent is called the “tissue window” 
(see Figure 4C). At shorter wavelengths (e.g. UV region) 
endogenous chromophores, such as haemoglobin, 
myoglobin, cytochromes, nicotinamides, flavins and 
melanin, as well as some pigments such as bilirubin might 
absorb the excitation light before it reaches the PS at which 
it is targeted. Hence light penetration into tissues at ~630 nm 
is limited to ~ 1- 3 mm. At longer wavelengths (> 1000 nm) 
the absorption by water will prohibit the delivery of light 
deep inside tissues. At high PS concentrations the so called 
“self-shielding” (the absorption of light by the PSs itself) 
may also impair penetration deep into tissues. Unfortunately 
the longer the wavelength of the excitation light the lower is 
its energy (photon energy), which restricts its potential to 
excite a one-photon process due to molecular systems 
lacking optical absorption on going from the red to near-
infrared wavelengths. A way around this is the use of two-
photon (or multiphoton) excitation (2PE), achieved by using 
a femtosecond pulsed Titanium:sapphire laser with high 
peak powers (Figure 4) [4, 5, 16, 28, 43, 50, 51] (see 
sections 5.2 and 5.3 for more details). 
Figure 4 Multiphoton excitation of tissues in the near-infrared reduces scattering and hence improves light penetration and localised light delivery. A 
Nonlinear processes in the focal volume of a multiphoton microscope depending on the energy delivered by a high peak power femtosecond pulsed laser 
[52]. B Excitation of a PS to the first excited singlet state (S1) by either one-photon (1P), two-photon (2P) or three-photon (3P) absorption. Virtual states 
are indicated by dashed lines. For example, in principle an excited state formed by absorption at 300 nm may also be generated by simultaneous 
absorption of two photons at 600 nm or three photons at 900 nm, although the efficiency (photon absorption cross section) for excitation falls dramatically 
from 1P to 3P excitation. C Absorption spectrum of tissue, showing the “tissue window” in the region of 650-900 nm (C is adapted from Weissleder and 
Ntziachristos (2003) [53]). 
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 Following PDT treatment be it single or more photon 
induced cell killing is thought to be brought about by three 
connected mechanisms, including direct cytotoxicity of 
reactive species towards tumour cells, shutdown of the 
tumour vasculature which may lead to hypoxia in the tumour 
and an inflammatory immune response. Since there are 
several processes involved in causing PDT induced cell 
killing it is not surprising that any of the three commonly 
known cell death mechanisms, namely apoptosis, necrosis or 
autophagy can be triggered [5, 10, 23, 26, 54]. Confocal 
microscopy and Förster Resonance Energy Transfer (FRET) 
imaging on cultured cells demonstrated that common PDT 
PSs are found to localize in different subcellular structures 
such as the plasma membrane (Photofrin®), mitochondria 
(phthalocyanine Pc4), lysosomes, nucleus, endoplasmic 
reticulum or the Golgi apparatus [5, 23, 26, 43, 55]. 
 The extent to which each cell death pathway is triggered 
depends on the PS type, dose and intracellular localization, 
as well as the tissue type, tissue oxygenation levels and the 
light dose used. Therefore the accurate prediction of the 
treatment outcome is very challenging [10, 23, 26].  
 The effect that PDT has on the formation of blood 
vessels was first described in 1989 when it was shown that in 
many cases endothelial cells of the tumour vasculature may 
be the primary target of PDT in vivo. There have also been 
indications that hypoxia, nutrient depletion and oxidative 
stress in tumours is caused by a PDT induced shutdown of 
the tumour vasculature. This may not only induce secondary 
necrosis, but also lead to the overexpression of vascular 
endothelial growth factor (VEGF) to make up for the loss of 
blood vessels. Hence the combination of PDT with 
antiangiogenic agents has been suggested to improve PDT 
treatment outcomes [5, 23, 26, 54]. 
 Furthermore several groups report that PDT triggers an 
inflammatory immune response at the tumour site. Efforts to 
improve tumour control using a combination of PDT in 
conjunction with immunotherapy to enhance the therapeutic 
response may prove to be beneficial [10, 51, 54, 56]. It is 
generally believed that apoptosis is the main cell death 
pathway following PDT and can be triggered by treatment of 
low light doses. Apoptosis is also thought to cause lower 
inflammation levels than PDT-induced necrosis and may 
lead to antitumor immunity. Necrosis is often observed when 
using higher light doses in PDT, which inactivates enzymes 
such as caspases [5, 23].  
 PSs localized in the plasma membrane have been shown 
to preferentially induce necrotic cell death pathways which is 
not surprising due to membrane disintegration and the 
resulting depletion of intracellular ATP. Photosensitizers that 
are primarily localized in mitochondria (e.g. benzoporphyrin 
derivatives) frequently induce apoptosis by activation of 
caspases and cytochrome c [26, 43]. Overall the consensus is 
that apoptosis and necrosis have the same initial triggers, but 
the presence of caspases determines which cell death 
pathway the treated cells will undergo [23]. In some cases 
autophagy was also found to inhibit or enhance cell death 
after PDT [26]. Lipophilic PSs generally accumulate in a 
range of intracellular membranes. Pyropheophorbide-methyl 
ester (a synthetic derivative of Chlorophyll a) has for 
instance been reported to accumulate in the endoplasmic 
reticulum, Golgi apparatus, lysosomes and mitochondria. 
Photosensitizers that selectively localize in lysosomes have a 
higher tendency to aggregate and are hence seen to induce 
cell killing following irradiation with a significantly lower 
efficiency than agents that are found in other organelles. 
Targeted PSs that are conjugated to receptor ligands are 
commonly seen to trigger the endosomal-lysosomal pathway 
following internalization [43]. In 2000 Dahle et al. showed 
by in vitro experiments that not only cells directly affected 
by PDT undergo cell death, but also cells that are adjacent to 
them can suffer lethal cell damage (“bystander effect”) [57]. 
More recently an opposite “bystander effect” leading to an 
increase in cell proliferation in HeLa cells at the single cell 
level under a low dose of protoporphyrin IX (PpIX) 
sensitized ROS was reported by the Ogilby group [58]. 
4. TECHNOLOGICAL CHALLENGES AND 
DEVELOPMENTS IN PDT 
4.1. Progress in photosensitizer (PS) development 
 The most common clinically used PSs for PDT to date 
are molecules with a tetrapyrrole backbone such as 
porphyrins (irradiation at ~ 630 nm) and its analogues 
including benzoporphyrins, chlorins, bacteriochlorins, 
pheophorbide α, phthalocyanines and texaphrins. However, 
much research activity has been devoted to demonstrating 
PSs based on other molecular structures for both pre-clinical 
and clinical studies, e.g. fullerenes [17, 43, 59-61].  
 To date a range of PSs has been approved for the 
treatment of cancer and other conditions in the clinic. 
Photofrin® (trade name for the water-soluble 
hematoporphyrin derivative HpD or porfimer sodium) was 
the first PS agent to be approved by the U.S. Food & Drug 
Administration (FDA) for clinical use in the treatment of 
superﬁcial bladder cancer in the early 1990s. It is the one 
most commonly used PS for the clinical treatment of 
neoplastic lesions such as oesophageal, head and neck, skin 
and some lung cancers to date, despite the fact that it causes 
long lasting photosensitivity in patients. Other 
hematoporphyrin derivatives that were clinically evaluated 
for the treatment of various cancers and other conditions 
such as bacterial infections include Photosan® [62, 63] and 
Photogem® [64, 65].  
 This was followed by the approval of the chlorine based 
PS Foscan® (temoporfin, excitation at 652 nm), which 
proved successful in the treatment of skin, lung, bile duct 
and head and neck cancer, as well as other chlorin-based 
photosenstitizers including HPPH, SnEt2 (Puryltin), 
Talaporfin (L511, MACE, NPe6) and chlorin e6-
polyvinylpyrrolidone (Photolon®) and derivatives for the 
treatment of a variety of neoplasms [5, 51, 66, 67]. The non-
fluorescent PS precursor 5-aminolevulinic acid (5-ALA, 
trade name Levulan®) enhances the intrinsic production of 
protoporphyrin IX (PPIX) in mitochondria, which is 
activated by light illumination (~ 635 nm) following 
accumulation at the treatment site leading to the effective 
generation of reactive oxygen species within treated cells 
and triggering cell death [17, 68, 69]. The clinical use of 
topically applied 5-ALA for PDT was first introduced in 
1990 [70] and followed by a wide range of clinical and pre-
clinical studies for the PDT treatment of bladder cancer [71-
73], chronic polyarthritis [74], malignant glioma [75], non-
melanoma skin cancers such as actinic keratosis (in 
combination with fluorescence dosimetry) [69, 76], Barret’s 
oesophagus and even multidrug resistant leukemia, the latter 
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without much success [77]. In 2013 Bader et al. reported a 
clinical trial using hexaminolevulinate (HAL), a 5-ALA 
derivative, for the PDT of bladder cancer in humans. HAL 
activation was achieved using incoherent white-light (380 – 
700 nm) delivered through a 1.5 mm diameter quartz fibre 
(2-6 W transmission) integrated in a flexible irradiation 
catheter. HAL PDT showed good efficiency and minor 
reversible bladder irritability [78].  
 Other PSs and precursors that are available pre-clinically 
or in the clinic include Metvix (methylaminolevulinic acid) 
for the treatment of the skin conditions actinic keratosis and 
basal cell carcinoma, LS11 (talaporfin sodium), which is 
undergoing trials for the treatment of colorectal cancer, 
glioma and hepatocellular cancer and Tookad (Padoporfin, a 
Pd-bacteriopheophorbide, 763 nm) for the deep vascular-
targeted PDT of prostate cancer [5, 51, 66]. There has been a 
considerable effort to develop PSs with further red shifted 
absorption spectra to improve their activation at depth within 
tissues. One of the most successful examples for these efforts 
are phthalocyanine based systems, of which some derivatives 
show selective accumulation in tumours. They are non-toxic 
in their ground state and efficiently generate long lived 
triplet states and ROS leading to cell killing. The 
phthalocyanine Pc4 (silicon phthalocyanine, 675 nm) entered 
the clinic where it is used for the treatment of cutaneous T-
cell lymphoma. Several water-soluble phthalocyanines 
showed promising PDT efficiency, as well as 
naphthocyanines which absorb at longer wavelengths (740 – 
780 nm). It is hoped that the longer excitation wavelength 
would allow treatment at greater depth in tissues [5, 9, 59]. 
The texaphyrin Antrin® (Motexafin lutetium, 732 nm) is 
another long wavelength PS that received clinical approval 
for the treatment of breast and prostate cancer [5, 79-81]. 
The natural product hypericin has been suggested as PS for a 
less invasive PDT treatment of recurrent head and neck 
squamous cell carcinomas, because of its ROS generation 
efficiency, tumour selectivity, fluorescence imaging 
capabilities and low dark toxicity. The PDT efficiency of 
hypericin excited at 593 nm (150 mW, up to 60 J/cm2) using 
a Nd:YAG laser was tested in vitro and in vivo delivering 
evidence that it might be a clinically useful PS [82, 83]. 
Erythrosine is another potentially useful PS for PDT that 
accumulates in mitochondria as was shown on premalignant 
and malignant oral cell lines [84]. PDT is currently most 
successfully used in the palliative treatment of age-related 
macular degeneration (AMD) using the PS Visudyne® 
(verteporfin, 690 nm), a derivative of benzoporphyrin, for 
which it was approved by the FDA in 2000 [4, 5, 10, 20, 24, 
28, 59, 85]. The combination of conventional PDT PSs with 
different synergistic drugs has been found to be beneficial to 
treatment outcomes. Experiments on human breast cancer 
cells demonstrated that cell killing and therefore PDT 
efficacy can be significantly increased by synergistic 
treatment with the glycolysis antagonists 2-deoxy-glucose or 
3-bromopyruvate, but the underlying mechanism for this 
remains unclear [86]. The administration of calcitrol, an 
activated derivative of Vitamin D3, prior to 5-ALA delivery 
on squamous skin cancer in mouse models increased the 
accumulation of protoporphin IX in the tumours and hence 
the efficiency of 5-ALA-PDT [18]. Combining the 
conventional PDT treatment with the administration of 
VEGF has been shown to improve the treatment outcomes 
with PDT by preventing the formation of tumour 
neovasculature [5, 23]. 
From a biological point of view appropriate PSs should 
display low dark-toxicity, no or low photosensitization of the 
skin or other unwanted side-effects, rapid and selective 
uptake into target tissues (tumours), as well as reproducible 
application as part of a PDT protocol. Biophysically an ideal 
PS should firstly strongly absorb light at a specific 
wavelength in the red or NIR region (650 – 850 nm) of the 
spectrum, where light penetrates deeper into tissues, 
secondly display the efficient generation of cytotoxic 
species, such as reactive oxygen species (ROS) upon 
irradiation or as some newer PSs, such as combretastatins, 
lead to a directly acting drug without the generation of ROS, 
and lastly exhibit high photostability and demonstrate 
fluorescence to allow monitoring of their uptake into 
tumours. From a pharmaceutical viewpoint other 
advantageous features are simple large scale synthesis, good 
amphiphilicity (water-solubility for delivery and lipophilicity 
for targeting), chemical stability, limited aggregation, and 
rapid break-down into non-toxic metabolic products and 
excretion from the patient’s body after the PDT treatment [3-
5, 15, 19, 25, 28, 42, 43, 59]. As yet there exists no optimal 
PDT PS that matches all of the desired requirements and 
therefore the development of useful new and clinically 
relevant PSs is essential. 
 Photosensitizers can be broadly divided into three 
categories, namely first, second and third generation PSs. 
First generation PSs such as Photofrin® and HpD were 
found to lead to extended skin photosensitivity and are often 
given as part of a palliative care pathway [5, 42]. To 
overcome the undesired photosensitization caused by first 
generation PSs and shift the PS activation to longer 
wavelengths second generation PSs (e.g. chlorins, 
bacteriochlorins and phthalocyanines) were developed. Third 
generation PSs were designed to improve selective tumour 
targeting and drug accumulation by conjugating common 
PSs to carriers such as cholesterol, antibodies, and liposomes 
and therefore reduce unwanted damage to healthy tissues [5, 
42, 69, 78]. The section on targeted PDT below (4.7) will 
cover these developments in more detail. 
4.2. Light sources for PDT 
 The light source chosen for PDT treatment has a 
significant effect on the results that can be achieved. The 
choice of light source depends on its cost, reliability, size, 
available fluence rate (light dose), the PS used, the location 
of the disease site, as well as on the treatment depth inside 
tissue that needs to be achieved [5, 32, 69]. Ideally excitation 
wavelengths in the red or NIR (“tissue window”) are best, as 
the penetration depth in tissues is improved compared to the 
UV or visible range. The main types of light sources that can 
be used for PDT are lasers, LEDs and filtered lamps (e.g. 
fluorescent tubes, metal halide, xenon arc, high pressure and 
incandescent filament lamps) [10, 28, 69]. Since the 
invention of the Finsen lamp there has been much 
technological development leading to improved light 
sources. Early light sources that are mainly used for 
dermatological applications were often conventional white 
light lamps used in combination with filters to obtain PS 
activation at a certain wavelength. Overall the most common 
light source used in PDT are lasers which deliver 
monochromatic, coherent light and hence facilitate light 
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dosimetry. Dye lasers, pumped by a tuneable argon-ion laser 
(~ 5 -10 W), that can be matched to the excitation 
wavelength of the PS (e.g. 630 nm for HpD) were commonly 
used clinically from the late 1970’s until the early 1980’s. In 
the 1980s Q-switched solid-state frequency-doubled 
neodymium-doped yttrium aluminium garnet Nd:YAG (KTP 
(Potassium titanyl phosphate for the second harmonic 
frequency conversion)) lasers became the standard light 
source for PDT, since they can provide high energy pulses 
and are more reliable than the previously used dye lasers. 
For two-photon applications shorter pulse lasers are required 
and tuneable mode-locked (~70 – 80 MHz repetition rate) 
femtosecond pulsed (~150 – 200 fs) Titanium:sapphire lasers 
that provide high peak powers (tens of kWs) are usually the 
light source of choice. The disadvantages of some of these 
advanced lasers is that they are rather expensive, bulky and 
may rely on external water cooling and a non-domestic (3-
phase) power supply. Furthermore the wavelength tuning can 
be complicated and may make these lasers less user friendly 
and suited to the clinical environment. More recently 
semiconductor diode lasers have become commercially 
available which generally come at a considerably lower cost 
than pumped dye lasers, as well as with automated dosimetry 
and power calibration features. Furthermore their relatively 
small size makes them more mobile. They do not rely on 
external water-cooling, are very reliable and can be powered 
from the domestic mains and are hence easier to maintain. 
The major limitation of diode lasers is that they are restricted 
to one wavelength (e.g. 630 nm) and need to be carefully 
chosen depending on the PS being used. The development of 
laser diodes with multiple wavelengths is highly desired [10, 
28, 32, 68, 87].  
 In some cases light emitting diodes (LEDs) may be used 
as alternative low cost light sources that provide narrow 
spectral bandwidths and high fluence rates for PS excitation 
in superficial cancers, such as skin lesions. LED arrays can 
be configured easily allowing to accurately define irradiation 
areas of different geometries, e.g. linear arrays can be used 
endoscopically [10, 28, 69]. 
 When lasers are used the light is often delivered to the 
tissue of interest through optical fibres coupled to the laser. 
Optical fibres also benefit from being readily incorporated 
into an endoscopic device making the light source easily 
inserted into areas such as the lungs, oesophagus, digestive 
tract and the bladder for PDT. Additionally inflatable 
catheters that are coated with a scattering material on the 
inside are available for improved light delivery, e.g. in 
bladder cancer. Implanting light sources in solid tumour for 
deep tissue treatment has also been proposed [5, 21, 28, 32]. 
 To make the light delivery to tissues for fluorescence 
diagnostics and PDT more efficient different groups have 
been working towards the development of minimally 
invasive endoscopic probes. One such minimally invasive 
and simple contact endoscopic probe with an outer diameter 
< 1.5 mm that is inserted inside a conventional biopsy needle 
has been presented Göbel et al. (2012). Their probe delivers 
a field of view of up to several hundred microns with a pixel 
resolution of ~ 4 µm determined by the distance of fibres 
within the fibre bundle. Using an in vivo animal model they 
were able to simultaneously detect and image the 
fluorescence of deep seated brain tumour tissue and its 
vasculature [88]. 
4.3. Two-Photon PDT (2P-PDT) 
 The use of two-photon excitation (2PE) of PSs in the 
NIR between 600 - 1100 nm (“tissue window”, Figure 4C) 
has been suggested as an innovative approach compared with 
conventional PDT. The main advantage of using 2PE in PDT 
is the significantly improved penetration depth of the 
excitation light in tissues compared with UV or visible light, 
which is strongly absorbed by endogenous chromophores 
such as haemoglobin or melanin [17, 28, 29, 51, 85, 87, 89]. 
In the life sciences two-photon and multiphoton excitation 
with NIR light has been successfully used for the imaging of 
thick biological specimens with reduced photo-damage and 
improved 3D sectioning compared to conventional scanning 
confocal microscopy [17, 87, 90]. Exposure of a PS to ultra-
short (< 1 picosecond, ps) pulses of NIR light allows 
efficient “simultaneous” absorption of two photons by the 
chromophore in the ground state leading to the same excited 
state as commonly achieved by one-photon excitation 
(Figure 4B), as long as the overall energy provided is 
equivalent. Hence PS activation is also followed by the same 
photodynamic processes normally induced by one-photon 
excitation, but with improved treatment depth and selectivity 
to the treatment area [5, 17, 25, 28, 51, 87]. Other 
advantages of 2PE are the highly localized light delivery 
restricting PS excitation to a very small (femtolitre) confined 
three dimensional volume and therefore reduction of damage 
to collateral healthy tissue or potential to target individual 
tumour blood vessels. Compared with one-photon excitation 
for PS activation laser-induced hyperthermia and therefore 
phototoxicity is reduced when using 2PE, as NIR light 
scattering and absorption in tissues is lower compared with 
the absorption of UV or visible light by biological molecules 
[5, 17, 25, 28, 29, 50, 51, 85, 87, 89, 91]. Furthermore 
previously unsuitable PSs with excitation in the UV may 
now be explored by the 2P or multiphoton process using 
visible and NIR femtosecond light. 
 There exist two potential types of two-photon PDT (2P-
PDT), type one being simultaneous (resonant) and the other 
two-photon/two colour [28]. Here we will focus on the more 
common type of two-photon absorption for PS activation. 
The ‘simultaneous’ absorption of two photons (within 10-15 
s) was first theoretically predicted by Maria Göppert-Mayer 
in 1931, but it was not demonstrated experimentally until the 
development of the first lasers in the 1960’s due to the large 
light intensities needed to trigger this low probability 
photophysical and photochemical process [92]. The two-
photon absorption cross-section of a molecule is a measure 
of the efficiency with which it will undergo a two-photon 
absorption process, and the higher it is the higher will be the 
chance of a two-photon process taking place. The two-
photon absorption cross-section (σ2) is measured in Göppert-
Mayer units (1 GM = 10-50 cm4 s photon-1 molecule-1) [28, 
85, 87, 89, 93]. For example the widely studied PS Photofrin 
has a two-photon absorption cross-section of only 3 GM at 
800 nm [94], whereas molecules engineered for 2PA have 
cross-section values in the region of 103 – 104 GM (see 
below). 
 The “simultaneous” absorption of two photons of NIR 
light (longer wavelength, less energy) by the ground state PS 
is a non-linear two-photon process leading to the generation 
of a singlet excited state via a short-lived virtual intermediate 
state (10-15 s). Usually “simultaneous” 2PE is achieved using 
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short light pulses of ≤ 100 fs with high peak powers (from 
mostly tunable femtosecond mode-locked Titanium:sapphire 
laser, but more recently also pulsed diode and fibre lasers) at 
approximately twice the wavelength required to achieve one-
photon excitation. Two-photon photoactivation at depth in 
tissues using fs-lasers for excitation may still be limited 
when using conventional PSs (e.g. porphyrins) due to their 
usually small two-photon absorption cross-sections (3 – 16 
GM depending on derivative [95]) and the oxygen depth 
profile in tissues. As mentioned earlier photosensitization 
with clinically used PSs relies on Type II mechanism which 
requires the presence of oxygen, but tumour cores are mostly 
hypoxic (reduced oxygen) once they outgrow a certain size 
and the tumour neovasculature cannot supply sufficient 
oxygen to their centre anymore [5, 17, 28, 50, 85, 87]. 
 Over the last two decades the idea of using two photons 
of light instead of one to activate PSs in PDT at improved 
depths in tissues started to attract researchers’ attention and 
led to the development of novel PSs and light sources 
optimized for 2PE. A key issue regarding the 
implementation of two-photon methods is the need to 
improve the understanding of the depths at which PDT drugs 
can be photoactivated and the photodynamic dose. In terms 
of single photon activation the attenuation length is a key 
parameter describing the distance into the tissue or media 
where the applied light is reduced to approximately 37%. 
This parameter depends on numerous factors, including 
drug, ranging from 6.5 mm to ~ 1 mm for excised tumour 
and brain respectively using 600-700 nm light [30]. The 
ability to use further red-shifted wavelengths has potential 
benefits. To our knowledge the first studies investigating the 
use of 2PE for PS excitation were reported in the 1980’s. 
Andreoni et al. (1982) described the use of two near-UV 
photons (10 ns pulsed nitrogen laser, 337 nm, ~250 kW peak 
power, 30 Hz repetition rate, 20 mW/cm2 peak irradiation 
intensity) to excite HpD and achieve the PDT effect on rat 
thyroid epithelial cells [96]. They did not fully exploit the 
potential of 2PE because the advantage of increased depth of 
PS activation is better suited when using red or NIR light, as 
discussed above, is absorbed significantly less by intrinsic 
chromophores and also benefits from being scattered less 
within tissue. Shortly after Bodaness and co-workers 
reported the 2PE of the PS HpD using a Q-switched Nd:YG 
laser at 1064 nm [97] or an alexandrite laser at 750 nm in 
solution [93] in 1985. The first demonstration of 2PE on in 
vitro cultured oesophagus cancer cells by a Q-switched 
Nd:YAG laser emitting at 1064 nm for deeper activation 
depth in PDT of HpD dates back to 1986 [98] and was 
followed by investigations using the even more efficient 
two-photon PS pheophorbide a [99]. Almost a decade later 
the use of 2P-PDT in the treatment of bacterial infections 
(Salmonella typhimurium) using psoralen derivatives 
activated by irradiation with a pulsed mode-locked 
Ti:sapphire laser in vitro was successfully demonstrated 
[87]. 
 It was soon recognized that commonly used PSs such as 
Photofrin® have too low two-photon absorption cross-
sections (~1 - 100 GM), require extended illumination with a 
tightly focused laser beam, and are therefore unsuited for the 
development of clinical 2P-PDT [5, 7, 28, 50, 87, 89, 100]. 
Hence there has been much activity by way to develop novel 
PSs with improved two-photon absorption properties whilst 
at the same time retaining good pharmacological properties 
for their clinical application. Some molecular design features 
are considered to enhance two-photon absorption properties 
of organic molecules including the insertion of long electron-
rich π-conjugated chains, substitution with electron donating 
and accepting groups to increase intramolecular charge 
transfer properties and maintaining a planar molecular 
structure [50, 85, 101]. Some approaches towards the 
implementation of 2P-PDT and preparation of optimized 
two-photon PSs are discussed in the following.  
 In 1997 Bhawalker and his group reported the synthesis 
of a novel promising dye optimized for two-photon 
absorption called 4-[N-(2-hydroxyethyl)-N-
(methyl)aminophenyl]-4'-(6-hydroxyhexyl sulfonyl)stilbene 
(APSS). The molecule was shown to have a high two-photon 
absorption efficiency at 800 nm excitation (two-photon 
absorption coefficient β = 1.45 cm/GW) and to transfer its 
energy to a PS in solution leading to singlet oxygen 
generation by indirect activation in presence of molecular 
oxygen [102]. Four years later another group demonstrated 
that singlet oxygen was efficiently generated by excitation of 
4-(diphenylaminostilbene)-substituted porphyrin-based PSs 
molecularly designed for enhanced two-photon absorption at 
780 nm (within the “tissue window”) using a 150 
femtosecond pulsed laser [50]. The development of other 2P-
PDT agents such as lipophilic quadrupolar chromophores 
carrying anthracenyl and dibromobenzene residues [103] and 
hydrophilic conjugated porphyrin dimers [104, 105] with 
realistic and practical 2PA cross-sections having at least 
>100 GM (e.g. 8,000 – 17,000 GM for the porphyrin 
dimers), good photostability and high light absorptivity 
within the “tissue window” have also been reported. Other 
porphyrin-based PS with two-photon absorption cross-
sections of ~2000 GM bearing targeting peptide chains were 
described by Starkey et al. [51] (Figure 5A).  
 The quadrupolar chromophores demonstrated effective 
cell killing upon 2PE at 820 nm and the conjugated 
porphyrin dimers were shown to be suitable for 2P-PDT in in 
vivo AMD models [103-105]. Dahlstedt et al. (2009) 
investigated the effects of 2P-PDT using a range of 
conjugated porphyrin dimers with high two-photon 
absorption cross sections up to 17,000 GM. They found that 
P2C2-NMel was the most efficient dimer demonstrating 
effective two-photon adenocarcinoma cell killing when 
excited using a pulsed femtosecond laser at 920 nm (3.6 – 
6.8 mW, 300 fs, 90 MHz). Unfortunately the irradiation time 
required to achieve 50% cell killing using P2C2-NMel (180 s) 
was ~ 4 x as long as needed for the commonly used PS 
Visudyne® (44 s), when irradiating cell monolayers using a 
657 nm continuous-wave laser at 9.4 mW/cm2 after 18 h 
incubation with 10 μM of the drug of interest [89]. In 2013 
Ogawa and Kobuke reported the 2PE of water-soluble self-
assembled ethynylene-linked conjugated bis-imidazoyl-
porphyrins showing improved two-photon absorption cross-
sections compared with monomeric porphyrins as well as 
efficient singlet oxygen generation. Experiments on HeLa 
cells demonstrated two-photon excited photodynamic 
activities comparable to hematoporphyrin when irradiating 
for 5 min at 780 nm (2 mW average power) [100]. 
 Not all approaches towards 2P-PDT to date have been 
based on the design of novel PSs, and the clinically well 
characterized PS precursor 5-ALA (5-aminolevulinic acid) 
has also attracted significant attention as a potential agent 
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suitable for 2PE. Madsen et al. used 2PE and fluorescence 
microscopy of human glioma spheroids to show conversion 
of 5-ALA to protoporphin IX throughout entire spheroid 
volumes using an argon-ion pumped dye laser at 635 nm 
with a fluence rate of 10 mW/cm2. They found that the 2P-
PDT induced cell killing strongly depends on the light 
fluence rate used [107]. Beck et al. (2007) reported studies 
on C6 rat glioma cells incubated with 5-ALA for 4-5 h 
before excitation at 800 nm using a fs-pulsed Ti:sapphire 
laser. Their experiments revealed the successful 
photodynamic cell killing on cell monolayers when using a 
mean irradiance of 6.1 x 1010 W/cm2 [17].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Examples of PSs designed to have high two-photon absorption 
cross-sections. A Targeted porphyrin-based PS described by Starkey et al. 
containing the central singlet oxygen generating chromophore (black) to 
which are attached the conjugated groups (blue) that enhance the two 
photon cross section, σ2, to a value of ~ 2,000 GM at 820 nm enabling 
effective application at depths up to 2 cm in tissues. Also attached are two 
peptide units (R, red) that target the PS to the tumour [51]. B A 
nanoparticle-based PS in which a chromophore with high 2PA cross section 
(PFVCN) transfers excitation energy to the tetraphenylporphyrin (TPP) 
sensitizer within the particle. In this fashion the efficiency of singlet oxygen 
generation is increased 1000x fold [106].  
 Approaches towards the development of 2P-PDT for the 
clinical treatment of age-related macular degeneration 
(AMD), one of the most common causes for partial blindness 
of the elderly in the developed world, were reported by 
different research groups [17, 29, 85, 108]. One-photon PDT 
using Photofrin as PS for the treatment of wet AMD is well 
established in the clinic. The use of 2P-PDT is believed to 
enhance the selectivity of the AMD treatment at the 
abnormal vasculature in the eyes of patients. Two-photon 
excitation in vitro on vascular endothelial cells using 
Photofrin® (GM < 10) as PS (excited at 850 nm) showed 50 
% cell killing at high laser peak energies of 6300 J/cm2 [29]. 
In vivo experiments on highly vascularized chicken 
chorioallantoic membranes treated with Visudyne® (689 nm 
excitation) confirmed improved localised selectivity of 2P-
PDT compared with conventional one-photon PDT [108, 
109]. In a follow-on study using chicken embryos and mice 
with implanted tissue windows the same group found that 
verteporfin 2P-PDT for AMD might provide long-lasting 
complete blood vessel closure with high selectivity, but pre-
clinical and clinical studies are still required [91]. An 
example of the success of two-photon activation using 
verteporfin as PS is shown in Figure 6. Another study 
reported the localized single blood vessel closure using 2P-
PDT in a mouse window chamber model using newly 
designed conjugated porphyrin dimers as PSs with high 
efficiency. These PSs are suggested to be particularly 
powerful if administered in combination with anti-VEGF 
drugs that prevent the formation of novel abnormal blood 
vessels [85]. 
 In recent years several research groups proposed the use 
of nanoparticle-PS systems to improve the targeted drug 
delivery and the depth of PS activation by upconversion. 
Gao et al. used so called photodynamic nanoplatforms that 
combine the ability of tumour detection by MRI (magnetic 
resonance imaging) and activation by 2PE. The non-toxic 
nanoplatforms consist of a dye (TMPyP) encapsulated in a 
neutral, hydrophilic polymer matrix and selectively target 
cancer cells (C6 rat glioma cells) in vitro [25]. Another 
approach was proposed using mesoporous silica 
nanoparticles functionalized with a mannose derivative and 
containing 6850 units of a covalently encapsulated PS 
(MSN1-mannose, 118 nm diameter) for 2P-PDT. The 
MSN1-mannose nanoparticles were investigated in human 
breast and colon cancer cell lines, as well as xenograft 
tumour mice and shown to bind to lectins overexpressed in 
cancer cells. They have large two-photon absorption cross-
sections up to 8 MGM (~ 1200 GM per individual PS 
molecule) and therefore might be a promising tool for 2P-
PDT cancer therapy [11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Demonstration of blood vessel closure by two-photon PDT in the 
in ovo chicken chorioallantoic membrane as a model for AMD treatment. A 
Before treatment the blood flow in the direction of the thin arrows is 
observed. B After irradiation at 780 nm combined with Verteporfin in the 
area indicated by the circle, blood flow continues in the non-irradiated 
vessels, but ceases in the occluded vessel indicated by the thick arrows. 
Adapted from Samkoe et al (2003) [109]. 
New Approaches to Photodynamic Therapy AntiCancer Agents in Medicinal Chemistry, 2016, Vol. 0, No. 0….11 
A means proposed to achieve more efficient light delivery 
and improved photosensitization for two-photon PDT was 
based on polymer nanoparticles (~50 nm diameter) 
conjugated with the PS tetraphenylporphyrin. The two-
photon absorption cross-section and singlet oxygen 
generation efficiency of the PS upon 2PE were found to be 
increased due to efficient energy transfer from the 
conjugated polymer nanoparticle shell [110]. In 2012 Idris 
and co-workers reported the use of mesoporous-silica–coated 
upconversion fluorescent nanoparticles (UCNs) that convert 
NIR light penetrating deep into tissues to visible 
wavelengths thereby activating two PSs (MC540 and ZnPc) 
carried within the nanoparticles. Tumour growth inhibition 
in in vivo mouse models using these targeted UCNs was 
demonstrated upon 980 nm excitation with an inexpensive 
continuous wave laser diode [111]. Quantum dots have also 
been suggested as 2P-PDT agents that act as energy donors 
for the PSs (acceptors). An example is the use of lipid coated 
QD-chlorin e6 (Ce6) complexes (QD:Ce6 1:5) that can be 
excited by one- or two-photons (1030 nm, free quantum dot 
= 3325 GM, Ce6 = 13 GM) with an energy transfer 
efficiency of 80 % in solution. [112, 113]. These quantum 
dot complexes have not been evaluated using in vivo systems 
so far. In another nanoparticle system a dye with high 2PE 
cross-section transfers energy by Förster Resonance Energy 
Transfer within the particle to embedded 
tetraphenylporphyrin (Figure 5B) resulting in a very large 
increase in singlet oxygen generation by the PS on excitation 
at 810 nm [106]. 
 The targeted delivery of PSs is also of high importance 
when using 2PE. Celli et al. pointed out the potential of 
using multiphoton imaging for PDD (Photodynamic 
Diagnosis or Detection) in combination with PDT making 
use of the improved light penetration depth and localized 
fluorescence excitation in tissues in the NIR. This has 
recently been demonstrated in a nanoparticle construct in 
which a chromophore with a high two-photon absorption 
cross-section activates a conjugated PS via energy transfer 
(FRET) [7]. Starkey et al. (2013) compared the use of 
octreotate to target SST2 receptors expressed on tumour 
vessels and EGF receptor (EGFR) targeted peptides 
conjugated with porphyrin-based PSs for deep tissue 2P-
PDT treatment on xenograft mouse tumours. It was found 
that targeting of the SST2 receptors was more effective than 
that of EGFR as reduction of the tumour vasculature alone 
inhibited further tumour growth and also that short pulse 
lengths (~120 fs) provide the best depth efficiency [114]. 
 In 2008 significant regression of mouse breast and lung 
cancer xenograft tumours using a tetrapyrrole-based PS 
designed for 2PE was reported. Approximately 4 h after 
administration the novel 2P-PDT PSs were irradiated at 800 
nm with a femtosecond pulsed Ti:sapphire laser (1 kHz 
repetition rate, 600 – 800 mW average laser power, 10 – 20 
W/cm average irradiance) leading to tumour regression at a 
depth of up to 2 cm. Following these experiments the 
researchers proposed studies in larger animals, in which they 
expect to be able to excite the PSs effectively at a maximum 
depth of 5 – 7 cm [51]. In 2012 Spangler et al, demonstrated 
the synthesis of so called PDT triads for the treatment of 
FaDu Head and Neck SCC (HNSCC) xenograft mouse 
tumours at depths from 2 – 5 cm. The PDT triads are 
comprised of a synthetic porphyrin with a high two-photon 
absorption cross-section (2000 GM at 840 nm), a 
chromophore for NIR imaging of the triad localization and a 
small peptide that targets EGF receptors on the cell 
membrane that are overexpressed in some cancers. It was 
found that PDT-triad activation using a 150 fs pulsed laser in 
the NIR for 15 – 45 min (900 mW) led to tumour regression 
and some complete cures in the mice after 15 - 20 days as 
well as excellent wound healing [115]. Two years later the 
same group published the results of an advanced pre-clinical 
study on EGFR overexpressing HNSCC mouse tumours. The 
tumours were targeted with two separate dyads, both of 
which have an EGFR targeting moiety and an imaging agent 
for image-guided tumour resection or PS molecule 
respectively. Following the selective dyad uptake the beam 
from a Ti:sapphire laser was focused to 1 mm in diameter 
near the tumour surface (800 nm, 100 fs pulses, 1 kHz 
repetition rate, 800 – 900 mW) and scanned over the tumour 
for 20 – 25 min leading to two-photon PS activation and 
complete regression after 20 days [116]. Additionally in 
2015 Zou et al. demonstrated the selective blood-vessel 
closure and tumour growth inhibition in murine models upon 
2PE at 800 nm. They studied a series of water-soluble 
bis(arylidene)cycloalkanone PSs modiﬁed by polyethylene 
glycol (PEG). A PS candidate carrying two asymmetric 
tetraethylene glycol chains performed best and resulted in 
prolonged survival of the mice, hence indicating the 
feasibility of using simple molecules to construct novel 2PE-
PDT PS candidates [117]. 
4.4. Alternative Strategy for Two-Photon Phototherapy 
(2P-PDT) without ROS 
 We proposed an innovative approach, Type IV PDT, 
towards the development of a novel type of two-photon 
phototherapy (2P-PDT) using E-combretastatins as virtually 
non-toxic pro-drugs that can be converted to the highly 
cytotoxic anticancer drug Z-combretastatin by 
photoisomerization (Figure 7). This direct action of the 
photo-activated drug enables it to bind to its cellular target 
and induce cell death. Photoisomerisation of combretastatins 
represents a different PDT mechanism which unlike Types I 
and II does not require the presence of oxygen or as for Type 
III does not involve interaction of the drugs electronic 
excited triplet state with any other molecule to produce a 
cytotoxic species. 
 Combretastatins are natural products that like stilbenes 
exist in two conformations dependent on the geometry of the 
substituents relative to the central carbon-carbon double 
bond. This different geometry leads to different photo-
physical behaviour, which can be controlled and optimized 
for PDT. For example, the Z-(cis-) form is non-fluorescent 
whilst the E-(trans-)isomer is fluorescent (Figure 7A). The 
two isomers also have different biochemical behaviour. The 
Z-isomer binds effectively to tubulin (Figure 7B), therefore 
inhibiting polymerization to microtubules at nanomolar 
concentrations and halting cell division which eventually 
leads to cell death particularly in the rapidly dividing 
endothelial cells of the tumour vasculature. The E-isomer on 
the other hand does not bind so effectively and as such was 
found to be considerably less cytotoxic (2-3 orders of 
magnitude). The anti-vascular effects of Z-combretastatins 
led to phase I-III clinical trials in which a sodium di-
phosphate derivative of Z-combretastatin A4 (Z-CA4) was 
tested as potential anti-angiogenic anticancer agent. 
Unfortunately the combretastatin phosphate salt displayed 
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severe side effects such as cardiovascular toxicity that 
prevented the compound from making its way to the clinic 
[118, 119]. The E-combretastatin pro-drug uptake and 
distribution in live cells can be monitored by multiphoton 
FLIM imaging at 625 nm [120]. It was shown that E-
combretastatins accumulate rapidly in the cytoplasm of live 
CHO, HeLa and HUVEC (human umbilical vein endothelial 
cells) cells and particularly in lipidic environments such as 
lipid droplets at concentrations up to two orders of 
magnitude higher than that of the pro-drug in the 
surrounding medium [120, 121]. Mechanistically upon 
excitation of E-combretastatin the molecule is promoted to 
Figure 7 Type IV direct combretastatin activation by two-photon excitation. A Mechanism of one- and two-photon excited reversible E↔Z-
combretastatin photoisomerization (R= -OMe, -CN, -N(CH3)2, R’ = -OH, -F, -NH2). The fact that the low-binding E-isomers are fluorescent permits 
monitoring of their uptake and localization within target cells prior to photo-activation using fluorescence imaging at low laser powers. B 
Photoisomerization of E- to Z-combretastatin allows binding to its target site in tubulin leading to inhibition of microtubule polymerisation. In the 
following this causes a halt in cell division and eventually cell death. C Z-Combretastatin A4 induced apoptosis in CHO cell monolayers following 
photo-activation of E-combretastatin A4 (E-CA4) assessed by staining with annexin V AlexaFluor488 conjugate (green) and propidium iodide (red), 
respectively. E-CA4 (0, 10, 25, and 50  μM) was added to the live cells 2 h before irradiation of a 100×100  μm field for 10 min at 625 nm with 
increasing average laser powers at the sample (1.6, 3.1, 4.7, 6.3, and 9.4 mW). Cell killing with micrometre precision was achieved at optimized pro-
drug concentrations and laser powers (e.g. 2 & 3c or 2d) Figure 7C is adapted from Scherer et al. (2015) [122]. 
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its singlet electronic state by one- or two-photon absorption 
from which it decays by geometric conversion 
(isomerization) on a sub-nanosecond timescale to its Z-
isomer. It is a direct pro-drug activation without the need of 
the formation of a long-lived energy transferring triplet state 
and furthermore an oxygen-independent process. The 
photoisomerization process is reversible and depends on the 
wavelength used for excitation as it is commonly seen for 
stilbenes [123, 124]. 
 The trans→cis photoisomerization of combretastatins by 
one-photon excitation (with UV light) was first described by 
Pettit and Singh in 1987, who used this photochemical 
process to obtain higher yields of the pure and highly active 
cis-derivative [125].  
 Two decades later Hadfield and co-workers patented the 
trans→cis photoisomerization of combretastatins by 
excitation of the compound in a degassed benzene solution 
using a 400 W medium pressure mercury lamp. Gas 
chromatographic analysis demonstrated a rapid one-photon 
excited isomerization process of CA4 [126]. In taking this 
concept forward Bisby et al. have characterised the 
photoisomerization of combretastatins in solution through 
both one- and 2PE at 340 and 625 nm, respectively. A key 
result was the ability to perform highly selective E-
combretastatin pro-drug activation using a femtosecond 
pulsed Ti-sapphire laser at 625 nm within live mammalian 
cells that induced cell death within 24 h after irradiation. A 
major benefit of the two-photon activation of E-
combretastatins is the high spatial resolution that can be 
achieved with micrometre precision and the potential to 
activate the prodrug deep within tissue due to high 
penetration of red excitation light (Figure 7C). Furthermore, 
since the isomerization process is oxygen-independent it is 
predicted that combretastatins might also have high 
efficiency in hypoxic tumour centres where traditional PSs 
are completely inefficient [127].  
 The development of novel combretastatin derivatives 
with improved two-photon absorption properties whilst 
maintaining its pharmacological characteristics are underway 
including the synthesis of new molecules containing cyano-
substituents to improve intramolecular charge transfer 
properties [128]. Steps towards clinical trials are also a 
priority with the requirement to identify how effective 2PE 
drug activation in tissue can be. Preliminary studies in 3D 
tissue models has shown promising results achieving 
combretastatin photoisomerization at up to 1.7 mm depth in 
agarose gels [127]. Moving even further into the NIR region 
to photo-activate the pro-drug may also be beneficial in 
developing an optimised treatment regime and to this end 
three-photon excitation (3PE) of E-combretastatins at 
wavelengths >850 nm have also been demonstrated as a way 
to improve the depth limitations of PS activation in tissues 
[127, 128]. These studies are the ﬁrst to demonstrate the 
photoisomerization of stilbene derivatives for the 
development of a novel type of 2P-PDT processing the 
ability to function in a range of cellular environments, 
including hypoxic regions, such as tumour cores. 
 Currently 2P-PDT is a new and exciting treatment 
modality for cancer, and still in its infancy. Agostinis et al. 
suggested that two-photon PDT may become especially 
advantageous in the treatment of highly pigmented 
melanoma or deeper lying tumours [5]. The successful 
implementation of 2P-PDT in the clinic will depend on the 
development of inexpensive and reliable pulsed NIR lasers, 
two-photon endoscopic devices, the design of novel PSs with 
high two-photon absorption cross sections and good 
pharmacological properties, ways to target the drug delivery, 
as well as making the systems easy to use for the clinicians 
by providing stable treatment protocols [22, 28]. It has also 
been proposed that further depth of treatment may be 
achieved using three-photon excitation of PSs. The 3PE of 
hematoporphyrin IX (HpD-IX) was demonstrated in DMSO 
solution with an OPG-laser pumping at 1200 nm (25 ps-
pulse length) by Cohanoschi et al. (2006) showing useful 
three-photon absorption cross sections. The results indicate 
that imaging and PDT at increased depth in tissues may be 
possible making use of 3PE of PSs within the second “tissue 
window” between 1100 and 1300 nm [129]. 
4.5. Dosimetry 
 Now that a wide range of potential PSs has been 
developed, and advanced and affordable light sources are 
available, the demand for precise dosimetry in PDT is 
increasing, to ensure safe, controlled and reproducible 
treatment conditions. The fact that the light needs to pass 
through a range of media including complex optics, water 
and tissues is a major challenge in dosimetry [15]. A range 
of other factors contribute to precise dosimetry including the 
total light dose, the light exposure time, the fluence rate, the 
irradiation wavelength, drug-to-light interval and the light 
delivery mode (single, fractionated or metronomic at a low 
dose over an extended period of time). Also important are 
the type of PS used, its concentration and localization, as 
well as the availability of O2 in the tumour which is key to 
efficient ROS formation (only Type I and II) [5, 15, 28, 69]. 
Several of these parameters such as the light penetration, 
tissue oxygen and PSs concentration can fluctuate during the 
treatment [28]. Ideally clinical dosimetry protocols should be 
combined with computational modelling (e.g. Monte Carlo 
modelling) to predict the efficacy of PDT and optimise the 
treatment parameters based on PS fluorescence and singlet 
oxygen generation detection [130]. The development of 
precise PDT dosimetry is a major challenge because of the 
variety of parameters involved, but has the potential to 
become a useful tool in the development of patient 
customized treatments and the optimization of existing 
protocols. 
4.6. Photodynamic diagnosis/detection (PDD) 
 The term photodynamic diagnosis or detection (PDD) 
describes the detection and monitoring of PS localization, as 
well as the location, depth and size of tumours and their 
responses during PDT by using the fluorescence emitted by 
most PSs. Therefore the PS is irradiated at low laser powers 
that are sufficient for imaging compared with high powers 
that are required for PS activation. The relative powers used 
for imaging or activation are directly related to the PS used. 
PDD might potentially be beneficial in the diagnosis of early 
stage cancers and real-time optimization of light delivery 
parameters could help to improve treatment outcomes [3, 43, 
69]. For it to be clinically useful in detecting cancers, 
adjustment of the irradiation area is necessary and post-
treatment PSs need to display sufficient fluorescence which 
can be difficult because of PS photobleaching caused by the 
high light dose irradiation during PDT [15, 43]. PDD has 
been gaining attention by virtue of the number of clinical 
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trials showing its usefulness in the detection of bladder 
carcinoma. Since the late 1990’s there have been increasing 
efforts by numerous research groups to develop 
fluorescence-based cancer detection using the fluorescence 
from protoporphyrin IX (PpIX) which accumulates in 
tumours following the application of 5-ALA. Fluorescence 
detection using an incoherent light source was found to be a 
promising tool for the non-invasive endoscopic diagnosis of 
bladder cancer with high sensitivity and might potentially 
reduce the need for biopsies [72]. Under operating theatre 
conditions PDD also provides a real-time surgical indicator 
on potential cancer zones which aid and guide recognition of 
areas in need of treatment and may even lead to an 
automated self-targeting detection and treatment single-shot 
device. Furthermore the use of photodynamic detection 
(PDD) following 5-ALA, hexyl-ALA or hypericin 
administration by transurethral resection of bladder tumours 
is hoped to lower cancer recurrences [131]. Others suggested 
to further improve the efficiency of PDD by time-resolved 
endoscopic detection using the measurement of fluorescence 
lifetimes on the subcellular level [68]. 5-ALA PDD was not 
only investigated in bladder cancer, but also proved 
promising for the intraoperative identification and resection 
of malignant glioma [132, 133]. The development of 
interstitial PDT (iPDT) using implanted light sources (e.g. 
cylindrical light diffusors) for PS excitation in malignant 
glioma patients is also well underway showing that strong 
fluorescence intensities reporting high concentrations of 
PpIX in the tumour before treatment and complete 
photobleaching following PDT indicate favourable treatment 
results [134, 135]. In Europe the fluorescence diagnosis of 
bladder cancer after injection of hexaminolevulinate solution 
is clinically approved [136].  
 The non-invasive fluorescence monitoring of 
fluorescently labelled epidermal growth factor (EGF) in 
glioma cells has been suggested as a useful tool to 
differentiate between EGFR-positive and EGFR-negative 
tumours noninvasively prior to PDT [137]. PDD was 
recently evaluated in human malignant glioma biopsies 
(from 33 patients) that received 5-ALA PDT. Researchers 
looked for changes in fluorescence (non, weak, strong) to 
determine cell density and tissue type and were able to 
differentiate areas of solid tumours and tissues infiltrated by 
tumour cells, which may be useful during tumour resections 
[138]. An alternative approach is the monitoring of singlet 
oxygen luminescence (SOL). Comparison of SOL-based 
dosimetry with PS (PpIX) photobleaching and re-
accumulation following PDT in erythema showed that even 
though SOL can be a useful parameter to predict the tumour 
response absolute fluorescence photobleaching is sufficient 
[139]. 
4.7. Targeted photosensitizer delivery 
 Recently several research groups reported the 
development of methods for more effective and targeted PS 
delivery to specific molecular targets (receptors) expressed 
by tumour cells or tumour vasculature, e.g. by attaching a PS 
to monoclonal antibodies or antibody fragments with 
specificity to certain molecular targets, or encapsulation in a 
lipoprotein shell. The latter also protects the drugs from 
enzymatic or macrophagic digestion before reaching its 
target site. Gold nanoparticles, peptides, proteins such as 
transferrin, EGF or insulin, low density lipoproteins (LDL), 
folic acid, carbohydrates, somatostatin and liposomes have 
also been considered as delivery vehicles for PSs [5, 8, 61]. 
Some groups suggest that an ideal drug delivery system 
should ensure the PS delivery into the cell nucleus from 
where it would have a more detrimental effect compared 
with PSs that accumulate in the plasma membrane (such as 
porphyrins), Golgi or mitochondria. One way to achieve the 
selective nuclear delivery of the PS was reported by Ogura et 
al. who chemically tethered the PS chlorin to poly-L-lysine 
[61, 140]. 
 Photoimmunoconjugates (PICs) are complexes for the 
targeted delivery of PSs that consist of a NIR activatable PS 
(such as benzoporphyrin derivative monoacid A or 
phthalocyanines) and cancer cell targeting antibodies (e.g. 
cetuximab) which bind to overexpressed enzymes or 
receptors in the neoplastic tissue or tumour vasculature [7, 
141, 142]. Photoimmunotherapy using a NIR absorbing 
phthalocyanine (IR700) conjugated to monoclonal EGFR-
binding antibodies triggered in vivo xenograft tumour 
shrinkage after irradiation with NIR light in EGFR 
overexpressing cells. Furthermore PIC fluorescence can be 
used to monitor the PS localization and accumulation [143]. 
Benzoporphyrin derivative monoacid-A conjugated to 
cetuximab, an anti-EGFR antibody, changes the PS 
localization within EGFR-positive cells from mitochondria 
to lysosomes. No phototoxicity was observed in EGFR-
negative cells [142]. When the same conjugate was 
additionally incorporated into Preformed Plain Liposomes to 
form so called photo-immuno-conjugate-associating-
liposomes (PICAL) PDT induced cell killing of ovarian 
cancer cells was further enhanced [144]. The evaluation of 
PICs in EGFR overexpressing mouse models of A431 
squamous cell carcinoma cells in which irradiation leads to 
fluorescence and ROS generation causing lysosome 
proteolysis showed cell killing of individual micrometastases 
[141]. Yano et al. 2011 proposed the addition of a sugar 
moiety to PSs to improve their targeting towards tumour 
cells which consume larger amounts of glucose than normal 
cells (Warburg effect) [3]. The preparation of a non-
conjugated tumour targeted NIR imaging agent and PDT PS 
based on heptamethine dyes (IR-808) which shows efficient 
light induced cytotoxicity towards cancer cells has also been 
reported [145].  
 Hasan et al. and others have found that the cellular 
expression levels of VEGF and EGFR in prostate, pancreatic 
and ovarian cancer cells are affected by PDT. These findings 
indicate that a synergistic treatment approach using PDT in 
combination with targeted agents might be more effective 
than the photodynamic treatment alone. Investigations in 
prostate cancer animal models showed that PDT leads to the 
accumulation of VEGF, which is believed to have an 
enhancing effect on tumour growth and metastasis. Using a 
synergistic approach administrating the VEGF-inhibitor 
bevacizumab (Avastin®) encapsulated with benzoporphyrin 
derivative in animal models of pancreatic cancer showed a 
significant reduction of lung metastases [6]. 
 In 2014 Hu et al. presented an approach towards the dual 
targeting of both neoplastic cells and the tumour 
neovasculature at the same time using newly designed PS-
factor VII conjugates that selectively bind to overexpressed 
tissue factor [8]. An alternative approach for the localized PS 
delivery is the use of a relatively easy to use portable “fiber 
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optic-based sensitizer delivery” device which has recently 
been successfully tested on ovarian cancer cells. The device 
has a fluorosilane tip containing the PS pheophorbide (λex = 
669 nm) and a hollow fibre that delivers oxygen in vitro to 
generate ROS [146]. 
 The direct conjugation of PSs to oligonucleotides is 
another way to improve the targeted drug delivery into 
tumours. The PS (here chlorin e6) and antisense 
oligonucleotide (here Bcl-x SSO) polyplexes should ideally 
co-localize in endocytic vesicles. Irradiation should lead to 
PS induced ROS generation. The ROS cause disruption of 
lysosomal or endosomal membranes and hence 
oligonucleotide and PS release to the cytosol of the target 
cells, a process called photochemical internalization. This 
was shown to trigger cancer cell killing by a combination of 
PDT effects and gene therapy by oligonucleotide mediated 
oncogene modulation. The use of macromolecule-PS 
conjugates is believed to be a novel cancer treatment strategy 
and may be extended to the delivery of siRNA, antisense, 
single stranded origin (SSO) and miRNA antagomirs [147]. 
4.8. Nanoparticles in PDT 
 An alternative, more recent approach towards improved 
PS delivery in PDT, and already mentioned above in the 
context of metal and metal-coated complexes, is the use of 
nanoparticles [148]. Other forms of nanoparticles are 
spiropyran-based systems that shrink to less than half their 
original size (103 to 49 nm) upon irradiation at 365 nm and 
therefore show improved penetration, retention in tissues and 
controlled drug release. When encapsulating drugs such as 
docetaxel in these nanoparticles they are delivered into 
tumours and their vasculature more effectively and hence 
lead to improved treatment efficiency upon irradiation 
compared with the free drug as shown in mouse sarcoma 
tumour models [149]. 
 Not only may nanoparticles be employed to potentially 
improve PS delivery to its target site, but also to improve 
activation within tissues utilizing “upconversion”. A new 
class of nanomaterials that are relatively non-toxic are 
lanthanide-doped photon upconverting nanoparticles that 
transform long-wavelength low energy NIR light into shorter 
wavelength emission. These lanthanide systems demonstrate 
deep tissue penetration and are readily imaged deep inside 
tissues (up to ~ 3.2 cm in pork tissue) with low background 
emission enabling the potential to visualise the light-induced 
drug release and PDT action [150, 151]. On the downside the 
absorption cross sections of current upconverting 
nanoparticles is low and excitation at 980 nm can lead to 
water heating effects. This is hoped to be overcome by the 
development of novel Nd-YbEr/Tm tridopant upconverting 
nanoparticles that can be excited at 800 nm [151]. Yang et 
al. (2014) reported the preparation of silica-coated 
NaYF4:Yb,Tm@NaGdF4 upconverting nanoparticles with 
the PS hypocrellin encapsulated inside silica shells 
conjugated with folic acid for tumour targeting (λex = 980 
nm). They also showed that uptake of these upconverting 
nanoparticles into HeLa and HEK-293 cells and the 
triggering of cell death following irradiation with NIR light 
[150]. 
 
 
4.9. 3D model systems to study the effectiveness of PDT 
in vitro 
 As mentioned previously a major hurdle for PDT when 
using 2PE is to understand the depths of light penetration 
and distribution within biological tissue. 3D tumour models 
such as multicellular spheroids that mimic real tissues more 
realistically than cell monolayers have been recognised as 
useful tools to characterize light penetration and drug 
responses. As suggested by several groups they can be 
particularly useful in studying the effectiveness of PDT [152, 
153]. For example high-resolution fluorescence imaging of 
the clinically approved PS benzoporphyrin-derivative 
monoacid ring-A (BPD) in 3D models of ovarian cancer 
using illumination from a fibre optic micro-endoscope has 
been previously shown and suggested to be such a 
potentially useful diagnostic tool for studying in combination 
with PDT in 3D [152]. Furthermore Glidden et al. (2012) 
investigated the combination of fluorescence imaging to 
quantify the uptake, localization and photobleaching of BPD 
with PDT treatment using the same PS under different 
treatment conditions in 3D pancreatic carcinoma in vitro 
models [153] as illustrated in Figure 8.  
 
 
 
 
 
 
 
 
 
Figure 8 Use of verteporfin (BPD) as PS in a AcPC-1 tumour nodule 
model. These results demonstrate a) direct fluorescence imaging of PS 
uptake and localization by confocal microscopy, b) photobleaching of PS as 
a result of illumination (690 nm), and c) cytotoxic outcome from a 
combination of PS and illumination using a live (calcein AM/green 
fluorescence) - dead (propidium iodide/red fluorescence) assay. (Scale bars 
350 µm). From these combined measurements, it is suggested that 
parameters for PDT (dose, PS concentration) may be optimized. Illustration 
adapted from Glidden et al. (2012) [153]. 
 In 2013 Anbil et al. proposed a 3D model system of 
ovarian cancer spheroids to study the PDT response based on 
the correlation of live volume (fraction of live cells) and cell 
viability. A range of PS and light doses were tested 
demonstrating the most significant effects (reduction in live 
volume and cell viability) using 0.25 μM benzoporphyrin 
derivative (BPD) irradiated with a 690-nm fibre-coupled 
diode laser (irradiance of 150 mW∕cm2) [154]. Furthermore 
the real-time imaging of the uptake of E-combretastatins in 
multicellular spheroids (~ 400 – 600 µm diameter) as well as 
the highly selective spatial photo-conversion of 
combretastatin derivatives in three-dimensional agarose gels 
at depths up to 1.7 mm was demonstrated [127]. A key issue 
is the ability to determine the level of cell death deep within 
spheroids. It has been suggested to use computational 
analysis of the fluorescence images obtained from 3D model 
systems grown in a multi-well format to acquire high-
throughput quantitative information on growth inhibition and 
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cytotoxicity. Celli et al. recently reported the development of 
such a platform named qVISTA which is widely accessible 
to research laboratories with an inverted fluorescence 
microscope and modestly equipped PC [155]. 
4.10. PDT using PSs with antimicrobial effects 
 PDT has also been suggested as an alternative to treat 
bacterial infections particularly under the light of rising 
antibiotic resistances. Bacterial strains that show resistance 
to multiple antibiotics are effectively killed by PDT and are 
less prone to develop resistances [12, 156, 157]. Hamblin 
and co-workers reported the first proof-of-principle study 
using PDT to treat bacterially infected wound sites in mice 
by topically applying a poly-L-lysine and chlorin e6 
conjugate to the target site, which was activated with 660 nm 
laser light. It was shown that Escherichia coli bacteria 
responsible for infecting the wounds were rapidly killed by 
the treatment without harming healthy tissue in the mice 
[157]. This was followed by studies on other 
microorganisms such as Staphylococcus aureus and Candida 
albicans and using additional PSs such as rose Bengal, 
toluidine blueO and methylene blue. The poly-L-lysine 
chlorin e6 conjugate reported previously was found to be the 
most powerful on all microorganisms tested [156]. A range 
of conditions can potentially be treated using antimicrobial 
PDT and have been evaluated in preclinical or clinical 
studies including acne, gastric Helicobacter pylori infections 
and brain abscesses using acridines or hypericin as PSs [12]. 
4. FUTURE OUTLOOK & CONCLUSION – 
CHALLENGES AND FUTURE DIRECTIONS IN PDT 
 Since the 1970s, when PDT was first evaluated in clinical 
trials for cancer treatment using porphyrin derivatives as 
PSs, there has been a continuously increasing amount of 
research in the field. Hundreds of new PSs have been 
designed [43] with a more recent focus on targeted drug 
delivery by a range of groups. Gradually better and more 
cost-effective light sources are being developed and 
becoming commercially available (including portable pulsed 
diode lasers). The efficiency of PDT using a wide range of 
PSs has been evaluated extensively in vitro and in vivo, as 
well as in early stage clinical trials particularly in advanced 
cancers. Due to a lack of extensive phase III clinical studies 
PDT is still regarded as a niche option for the palliative care 
of very advanced cancers. Researchers in the field from the 
UK, USA, Denmark, South Africa and Germany feel that the 
field of PDT is narrowing down, particularly on the clinical 
aspect due to a lack of available funding for expensive 
advanced clinical studies. Nonetheless, the amount of 
fundamental research concerned with improving the tools for 
PDT such as PSs, drug delivery, light sources and dosimetry 
shows that the field is still very active. Currently the most 
promising clinical application seems to lie in the treatment of 
AMD and antibacterial PDT rather than cancer.  
 The use of 2PE for the activation of PSs has been shown 
to give an advantage over 1PE for PDT at improved depths 
in tissues with precisely localized PS activation and may be 
more effective in hypoxic tumour areas. This may also be 
particularly useful in the targeted PS activation at the 
vasculature. The company SensoPath Technologies, Inc. 
reports that they are moving rapidly into the clinic using 
targeted image-guided two-photon PDT for the treatment of 
HNSCC in dogs and cats. There are also plans to commence 
phase I and II human trials in the near future and to bring 
two-photon PDT to the veterinary market using next 
generation PDT agents. 
 The multifaceted nature of cancer certainly requires a 
variety of treatments to be made available. Ongoing 
technological, fundamental and clinical research fully 
supports a viable route towards establishing PDT as a 
mainstream cancer treatment modality or at the very least a 
treatment modality that can be used in combination to other 
cancer therapies. For PDT to become widely accepted, 
precise and reliable dosimetry of the light delivery, as well 
as the PS and oxygen concentration at the tumour site, are 
essential. The development of complete, inexpensive and 
efficient treatment packages for clinicians that include the 
light source, PS and a simple treatment protocol is highly 
desirable. 
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